Urogen Pharma (NASDAQ:URGN) Upgraded by Wall Street Zen to “Hold” Rating

Wall Street Zen upgraded shares of Urogen Pharma (NASDAQ:URGN) from a sell rating to a hold rating in a research note published on Saturday.

Other equities analysts also recently issued reports about the stock. HC Wainwright reiterated a “buy” rating and issued a $40.00 price objective on shares of Urogen Pharma in a report on Monday, October 27th. Piper Sandler assumed coverage on shares of Urogen Pharma in a research note on Monday, August 18th. They issued an “overweight” rating and a $36.00 price target on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Urogen Pharma in a report on Wednesday, October 8th. Finally, D. Boral Capital reissued a “buy” rating and set a $25.00 price target on shares of Urogen Pharma in a report on Monday, October 27th. Seven investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $32.00.

Urogen Pharma Stock Down 1.3%

Shares of NASDAQ:URGN traded down $0.30 during mid-day trading on Friday, reaching $23.24. 2,073,026 shares of the stock were exchanged, compared to its average volume of 1,132,570. The stock’s 50 day simple moving average is $18.68 and its 200-day simple moving average is $15.12. Urogen Pharma has a one year low of $3.42 and a one year high of $23.90. The company has a market cap of $1.08 billion, a P/E ratio of -6.72 and a beta of 1.06.

Urogen Pharma (NASDAQ:URGN) last issued its quarterly earnings results on Thursday, November 6th. The company reported ($0.69) EPS for the quarter, beating the consensus estimate of ($0.72) by $0.03. Urogen Pharma had a negative return on equity of 97,487.15% and a negative net margin of 170.59%.The firm had revenue of $27.48 million during the quarter, compared to analysts’ expectations of $34.09 million. Analysts anticipate that Urogen Pharma will post -3.12 EPS for the current fiscal year.

Insider Activity

In other news, General Counsel Jason Drew Smith sold 1,520 shares of Urogen Pharma stock in a transaction dated Monday, September 8th. The shares were sold at an average price of $19.11, for a total transaction of $29,047.20. Following the completion of the transaction, the general counsel directly owned 43,305 shares in the company, valued at $827,558.55. This trade represents a 3.39% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Chris Degnan sold 2,203 shares of the company’s stock in a transaction dated Wednesday, October 8th. The stock was sold at an average price of $16.85, for a total transaction of $37,120.55. Following the completion of the sale, the chief financial officer owned 2,280 shares in the company, valued at $38,418. This represents a 49.14% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 14,594 shares of company stock valued at $259,713 in the last ninety days. 4.70% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. Osaic Holdings Inc. grew its holdings in Urogen Pharma by 491.2% during the second quarter. Osaic Holdings Inc. now owns 3,695 shares of the company’s stock worth $50,000 after buying an additional 3,070 shares in the last quarter. CWM LLC grew its stake in shares of Urogen Pharma by 6,047.1% in the 1st quarter. CWM LLC now owns 5,225 shares of the company’s stock worth $58,000 after acquiring an additional 5,140 shares in the last quarter. State of Wyoming purchased a new position in shares of Urogen Pharma in the 3rd quarter worth approximately $66,000. Strs Ohio bought a new stake in shares of Urogen Pharma in the third quarter valued at $76,000. Finally, Tower Research Capital LLC TRC lifted its holdings in Urogen Pharma by 422.0% during the second quarter. Tower Research Capital LLC TRC now owns 6,891 shares of the company’s stock valued at $94,000 after purchasing an additional 5,571 shares during the last quarter. Institutional investors own 91.29% of the company’s stock.

Urogen Pharma Company Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.